Disease

Salivary Gland Neoplasms

Active therapeutic pipelineEmerging research

MeSHSalivary Gland Neoplasms

Publications

Clinical trials

2023

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Clinical trial2026-08-07Results posted · ClinicalTrials.gov

The evolving landscape of salivary gland tumors.

Research2023-07-25CA: a cancer journal for clinicians

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

2 clinical trials with recent milestones (1 completed or reporting results).

Major developments

Major trial resultsHigh impact

An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma

Results posted2026-08-28

Trial discontinuedImportant

Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Withdrawn2034-06-18

Clinical Milestones2View

Results posted 1

2026-08-28An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland CarcinomaResults posted

Other updates 1

2034-06-18Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaWithdrawn

Activity timeline2

Clinical trials

4 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Recently completed

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

Phase 1/2 · Completed · Klus Pharma Inc.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time

19532023

Most influential

Tumors of the major salivary glands.

Cancer · 1953 · 520 cites

The evolving landscape of salivary gland tumors.

CA: a cancer journal for clinicians · 2023 · 38 cites

Recent publications

The evolving landscape of salivary gland tumors.

CA: a cancer journal for clinicians · 2023 · 38 cites

Tumors of the major salivary glands.

Cancer · 1953 · 520 cites

Major themes4

Salivary Gland Neoplasms2
Adenoma, Pleomorphic1
Neoplasms1
Salivary Glands1

Leading journals2

CA: a cancer journal for clinicians1
Cancer1

Leading researchers8

Bates JE1
FOOTE FW Jr1
FRAZELL EL1
Hanna GJ1
Ho AL1
Kaka AS1
Saba NF1
Schmitt NC1

Affiliations (unnormalised)4

Dana Farber Cancer Institute1
Department of Pathology and Laboratory Medicine1
Memorial Sloan Kettering Cancer Center1
Winship Cancer Institute of Emory University1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Tumors or cancer of the SALIVARY GLANDS.

Identifiers

MeSHSalivary Gland Neoplasms

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.